Moderna CEO quits job in one day and cashes out full first year salary

Talk about a quick dash after getting cash!

Maddy Meyer/Getty Images

Maddy Meyer/Getty Images

On Wednesday, pharmaceutical company Moderna announced CFO Jorge Gomez left after just one day, but will still receive his full 12-month salary.

Prior to accepting a position at Moderna, Gomez served as Vice President and CFO of Dentsply Sirona Inc. since August 2019.

“This announcement follows the May 10 disclosure of Gomez’s former employer, Dentsply Sirona Inc., of an ongoing internal investigation into certain matters, including financial reporting,” Moderna said. company description.

An internal investigation in the matter will determine whether the incentives used to sell the dental supplier’s products to a wide range of distributors are “properly accounted for”. CNBC.

Gomez’s resignation took effect immediately, and the recently retired former CFO of the company David Meline filled the position in the midterm hiring process of the new candidate.

RELATED: Moderna shares surge after company says its Covid Booster will increase antibody levels against Omicron

Gomez was announced Appointed as Moderna’s new CFO on April 11th, effective May 9th.

“It’s an honor to join an organization focused on developing innovative medicines to solve major public health problems around the world,” said Gomez. at that time. “I look forward to working with the team on this great mission.”

Gomez’ is no longer entitled to any contract bonuses or future bonuses within a one-year period, but receives a salary of $700,000.

Denstsply Board Member and former Hillrom CEO John Groetelaars is currently serving as Interim CEO.

The news comes after the company announced on April 19 that Dentsply CEO Don Casey had been fired from the company after four years, three weeks before the company released its first-quarter 2022 results.

“The first quarter was a challenging quarter, and our financial performance and revised outlook reflect the impact of greater-than-expected macroeconomic headwinds and lower-than-expected earnings,” said Interim CEO Groetelaars. told shareholders.

On the other hand, Moderna exceptional first quarterThe stock surged more than 7% in premarket trading on Wednesday as Covid vaccine sales tripled to an estimated $5.9 billion in revenue.

RELATED: Moderna says vaccine is 96% effective in teens


Leave a Comment